AbbVie (NYSE: ABBV) reported Q3 EPS of $1.13, $0.07 better than the analyst estimate of $1.06. Revenue for the quarter came in at $4.94 billion versus the consensus estimate of $5.9 billion.

• Third-quarter sales growth was driven by the continued strength of HUMIRA and other promoted products. Global HUMIRA sales increased 19.6 percent on an operational basis, or 12.1 percent including the impact of foreign exchange rate fluctuations. Strong U.S. HUMIRA growth of 30.4 percent was driven by continued momentum across all three major market categories, rheumatology, dermatology and gastroenterology. International HUMIRA sales in the third quarter grew 7.1 percent on an operational basis, nearly double the rate of growth reported in the second quarter. Reported international HUMIRA sales growth in the quarter was reduced by 16 percent due to unfavorable foreign exchange.
• Third-quarter global IMBRUVICA sales were $304 million with U.S. sales of $267 million and international profit sharing of $37 million for the quarter.

Guidance:

AbbVie sees FY2015 EPS of $4.26-$4.28, versus the consensus of $4.24.

For earnings history and earnings-related data on AbbVie (ABBV) click here.